



Company name: KYORIN Holdings, Inc.
Representative: Minoru Hogawa
Representative Director, President
(Securities Code: 4569, TSE 1st Sec.)

Release of **Eklira**[®] 400μg **Genuair**[®] 60 inhalations, a treatment for COPD

TOKYO, JAPAN (June 1, 2016) - Kyorin Pharmaceutical Co., Ltd. ("Kyorin") (Head office: Chiyoda-ku, Tokyo, President: Mitsutomo Miyashita), a wholly owned subsidiary of KYORIN Holdings, Inc., announced the release of **Eklira**[®] 400μg **Genuair**[®] 60 inhalations, a treatment for COPD, both of which are for 30-day supplies. This was intended to synchronize with the timing of when prescription longer than two weeks is permitted as one year has passed since the launch of **Eklira**[®] **Genuair**[®] in May 2015.

Kyorin has been providing up-to-date information about **Eklira**[®] **Genuair**[®] that is a new long-acting anticholinergic inhalation medicine and a type of treatment for COPD that uses a novel dry powder inhaler **Genuair**[®] with improved operability. The release of the limitation for prescription will help the drug further contribute to improvement of the QOL in still more patients with asthma.

Kyorin will further contribute to patient treatment by enhancing the product lineup of its priority area of respiratory products and by continuing to provide up-to-date information.

The sales of the drug is factored in consolidated forecast for the fiscal year ending March 31 2017, which disclosed on May 12 2016.

■New product photo



■About 「**Eklira**[®] **Genuair**[®]」

Brand name : **Eklira**[®] 400 μg **Genuair**[®] 60 inhalations
Active ingredient : Acclidinium Bromide
Indication : Amelioration of various symptoms due to airway obstructive disorders in patients with chronic obstructive pulmonary disease (COPD) (chronic bronchitis and emphysema).
Dosage and administration :
Normally, the product is administered by inhalation twice daily (one inhalation of 400 μg of acclidinium bromide per administration) in adults.
NHI price : ¥ 6,244.40 per an inhaler (**Eklira**[®] 400 μg **Genuair**[®] 60 inhalations)
Date of Launch in Japan : June 1, 2016